What's next for ex-Metsera CMO Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Thu F 23 July, 2026

J.P. Morgan was the right banking team for Montara Therapeutics. Founder Nicholas Hertz trusted the team’s life sciences expertise, security, and support to focus on what mattered most. sponsored by J.P.Morgan

presented by HIV Ends Here: In­side Vi­iV Health­care’s Sin­gu­lar Mis­sion

news Lilly's triple agonist heads to regulators after two more Phase 3 obesity wins Exclusive: Obesity biotech Verdiva hires ex-Metsera CMO as crucial readouts near Roche says it is thoughtful on token use for AI, shelves a drug from Carmot buy Bioregnum The biotech recovery gathers speed in Q2

Jul 30 1:00 pm ET Accelerating Phase 1 decisions with liquid biopsy: From early signals to actionable insights sponsored by GUARDANT Aug 19 1:00 pm ET From pilots to production: AI across R&D, safety, regulatory, and clinical sponsored by IBM

Associate Director / Director, Preclinial Development - Immunology Terray Therapeutics, Inc. Monrovia, CA, USA Senior Director, Licensing Officer Bayer Cambridge, MA, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

The most differentiated science stays out of public view. This September, the Endpoints newsroom reveals the 11 private companies worth watching, live at the State Room in Boston. See the list first, reserve your spot and save with the early bird rate.

ENDPOINTS PHARMA How the FDA is unwinding the Makary era, and making way for a new commissioner Former cancer chief Pazdur says FDA has 'golden opportunity' to kill CDER and restructure FDA approves Nuvalent's cancer drug, a week after GSK closed $10.6B buyout Arrowhead’s gene silencer competitive with Ionis’ in triglyceride disease

in case you missed it 1. Q&A: Lilly returns to neuropsych and looks ahead to Alzheimer's prevention 2. Summit reports two-year survival data for Western patients, though context lacking 3. Vertex was only bidder for Crinetics in year's second-highest M&A premium 4. Crystalys gets $130M to take Sobi-rivaling gout drug to market 5. News Briefing Mentari adds $200M to migraine mission; Royalty's latest ATTR-CM deal